BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

Valley Wealth Managers Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Pfizer, Inc. PFE reported fourth-quarter 2021 adjusted earnings per share of $1.08, which comprehensively beat the Zacks Consensus Estimate of 85 cents per share. Earnings rose 152% year over year.

Pfizer (PFE) will report second-quarter 2023 results on Aug 1, before market open.In the last reported quarter, the company beat earnings expectations by 23.0%. Factors to Note. Pfizer’s ...

Pfizer (PFE) Positioned for Future Upside. Call options rising in open interest. By. Gordon Scott. Full Bio. Gordon Scott has been an active investor and technical analyst or 20+ years.